Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer
Clinical trial NCT03556358 · COMPLETED
Trial details
- NCT number
- NCT03556358
- Sponsor
- Tanvex BioPharma USA, Inc.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-06-28
- Primary completion
- 2020-11-27
- Enrollment
- 809
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.